Please login to read the full article.
Scrip Regulatory Affairs
EMA launches consultation on guideline on optional risk-based approach for ATMPs
01 February 2012
Amanda Maxwell
Please login to read the full article.
Not a subscriber ? Request a FREE Trial
Subscribe to Regulatory Affairs Pharma
RELATED CONTENT
NEWS
Scrip Regulatory Affairs News
- EU-wide consensus on confidential commercial data in drug marketing applications
- EMA responds to criticism of reflection paper on non-clinical studies for generic nano-particle iron medicinal product applications
- EMA responds to criticism of reflection paper on non-clinical studies for generic nano-particle iron medicinal product applications
- Feedback sought on EMA reflection paper on clinical testing for tissue-engineered products
Other Informa News
ANALYSIS
Regulatory Affairs Pharma Analysis
EDITORIALS
Regulatory Affairs Pharma Editorials
Other Informa Editorials
FEATURES
Regulatory Affairs Pharma Features
Other Informa Features
COMMENT
Regulatory Affairs Pharma Comment
Other Informa Comments
